SCHEMBL2816112

SCHEMBL2816112

OB(O)c1ccc(OCCN2CCOCC2)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
KDM4E B2RXH2 4/20 0.58
NPC1 O15118 3/20 0.57
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 1/20 0.53
MAPK1 P28482 2/20 0.51
RAB9A P51151 2/20 0.51
CYP1A2 P05177 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
HTR2A P28223 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN2A Q99250 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
SCN3A Q9NY46 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419399 0.86 ESR1 (0.57) KDM4EKMT2AHRH3LTA4H
SCHEMBL2810065 0.86 ALDH1A1 (0.54) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL1911879 0.85 NPC1 (0.69) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL13167914 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL10169462 0.81 ALDH1A1 (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL538618 0.81 ALDH1A1 (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL30402431 0.81 ALDH1A1 (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL1962706 0.81 ALDH1A1 (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL4978297 0.81 MAOB (0.54) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL26899393 0.79 KDM4E (0.56) ALDH1A1KDM4ENPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196357-B2 Biaryl compositions and methods for modulating a kinase cascade ATHENEX, INC. (US) 2019-02-05 US disclosed
US-20100249130-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2010-09-30 US disclosed
WO-2008127728-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196357-B2 Biaryl compositions and methods for modulating a kinase cascade MAP3K2, MAP3K3, MAP3K6 ALDH1A1 4063/4885KDM4E 1534/4885NPC1 2290/4885
US-20100249130-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE MAP3K2, MAP3K3, MAP3K6 ALDH1A1 4063/4885KDM4E 1534/4885NPC1 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.